Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 5/20 | 0.42 |
| ▸ | PARP1 | P09874 | 5/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.42 |
| ▸ | NAMPT | P43490 | 14/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717909 | 0.91 | TNKS (0.40) | TNKSPARP1PARP2NAMPTTNKS2 | |
| SCHEMBL4714688 | 0.88 | NAMPT (0.41) | TNKSPARP1PARP2NAMPT | |
| SCHEMBL4760969 | 0.80 | NAMPT (0.48) | NAMPT | |
| SCHEMBL4717908 | 0.79 | NAMPT (0.39) | TNKSPARP1PARP2NAMPTTNKS2 | |
| SCHEMBL4761797 | 0.78 | ITGB3 (0.53) | NAMPT | |
| SCHEMBL4760017 | 0.78 | ITGB3 (0.54) | NAMPT | |
| SCHEMBL4762284 | 0.78 | ITGB3 (0.53) | NAMPT | |
| SCHEMBL4761347 | 0.77 | NAMPT (0.43) | NAMPT | |
| SCHEMBL4714544 | 0.77 | NAMPT (0.47) | NAMPT | |
| SCHEMBL4791386 | 0.76 | ITGB3 (0.51) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |